Review explores the four main components—preconditions, triggers, reinforcers, and integrators—that facilitate personality change, alongside forces that maintain stability and prevent significant alterations in personality.
Immunovant’s $450M; Oncopeptides reassesses Pepaxti strategy in Europe; Akebia resubmits kidney drug
Immunovant goes for $450M: Immunovant’s early-stage autoimmune data will lead to a $450 million haul for the New York biotech, about $150 million more than